LIJUN: HK-listed firm has China’s IV market in the bag
Written by Andrew Vanburen (China Correspondent)
Tuesday, 16 February 2010 01:21
Lijun: China's largest manufacturer of non-PVC soft bag packaging IV infusion solutions.
LIJUN INTERNATIONAL Pharmaceutical (HK: 2005) saw its top line top 866 mln hkd in the first half of 2009, up from around 846 mln hkd a year earlier.
Its IV infusion products contributed 37% to revenue, but a quick look behind the figures reveals that these goods accounted for nearly 60% of its net profit over the period!
How does Lijun hope to boost growth via enhanced reliance on these higher margin products? Click here to see what its CFO told NextInsight recently.
